dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Grivas, P. |
dc.contributor.author | Loriot, Y. |
dc.contributor.author | Morales Barrera, Rafael |
dc.contributor.author | Teo, M. Y. |
dc.contributor.author | Zakharia, Y. |
dc.contributor.author | Feyerabend, S. |
dc.date.accessioned | 2022-02-22T07:53:40Z |
dc.date.available | 2022-02-22T07:53:40Z |
dc.date.issued | 2021-05-24 |
dc.identifier.citation | Grivas P, Loriot Y, Morales-Barrera R, Teo MY, Zakharia Y, Feyerabend S, et al. Efficacy and safety of rucaparib in previously treated, locally advanced or metastatic urothelial carcinoma from a phase 2, open-label trial (ATLAS). BMC Cancer. 2021 May 24;21:593. |
dc.identifier.issn | 1471-2407 |
dc.identifier.uri | https://hdl.handle.net/11351/7057 |
dc.description | Càncer de bufeta; Rucaparib; Carcinoma urotelial |
dc.description.sponsorship | The work was supported by Clovis Oncology (no grant number) and was designed by the sponsor, P. Grivas, and S. Chowdhury. |
dc.language.iso | eng |
dc.publisher | BMC |
dc.relation.ispartofseries | BMC Cancer;21 |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | Bufeta - Càncer - Tractament |
dc.subject | Inhibidors enzimàtics - Ús terapèutic - Eficàcia |
dc.subject.mesh | Urinary Bladder Neoplasms |
dc.subject.mesh | /drug therapy |
dc.subject.mesh | Poly(ADP-ribose) Polymerase Inhibitors |
dc.subject.mesh | /administration & dosage |
dc.title | Efficacy and safety of rucaparib in previously treated, locally advanced or metastatic urothelial carcinoma from a phase 2, open-label trial (ATLAS) |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1186/s12885-021-08085-z |
dc.subject.decs | neoplasias de la vejiga |
dc.subject.decs | /farmacoterapia |
dc.subject.decs | inhibidores de poli(ADP-ribosa) polimerasas |
dc.subject.decs | /administración & dosificación |
dc.relation.publishversion | https://doi.org/10.1186/s12885-021-08085-z |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Grivas P] Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, WA 98109, USA. Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA. Seattle Cancer Care Alliance, Seattle, WA 98109, USA. [Loriot Y] Department of Medicine, Gustave Roussy Cancer Campus, INSERM U981, Université Paris-Saclay, 94800 Villejuif, France. [Morales-Barrera R] Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Teo MY] Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. [Zakharia Y] Division of Hematology, Oncology, and Blood and Marrow Transplant, University of Iowa and Holden Comprehensive Cancer Center, Iowa City, IA 52242, USA. [Feyerabend S] Studienpraxis Urologie, 72622 Nürtingen, Germany |
dc.identifier.pmid | 34030643 |
dc.identifier.wos | 000657731100001 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |